, Volume 26, Issue 5, pp 783–788 | Cite as

Treatment of mercury vapor toxicity by combining deferasirox and deferiprone in rats

  • Marzieh Iranmanesh
  • S. Jamil A. Fatemi
  • Mohammad Reza Golbafan
  • Faezeh Dahooee Balooch


The hypothesis that combination of deferasirox and deferiprone chelators might be more efficient as combined therapy than single therapy in removing mercury from the body was considered. Male Wistar rats were exposed to mercury vapor for 2 weeks. After mercury administration some abnormal clinical signs such as red staining around the eyes, greenish mottling on the liver, weakness, loss of hair and weight, were observed in animals. Chelators were given orally after mercury vapor application for 2 weeks. Mercury toxicity symptoms in rats decreased after drug administration. After chelation therapy, these rats were anesthetized with ether vapor and immobilized by cervical dislocation and then their heart, liver, kidneys, intestine, spleen and testicles were sampled for determination of mercury and iron concentration. The combined chelation therapy results showed that these chelators are able to remove mercury from the body and toxicity symptoms decreased.


Deferasirox Deferiprone Mercury toxicity Chelation therapy Rats 


  1. Amiri A, Fatemi SJ, Fatemi SN (2007) Removal of thallium by combining desferrioxamine and deferiprone chelators in rats. Biometals 20:159–163PubMedCrossRefGoogle Scholar
  2. Cappellini MD (2008) Long-term efficacy and safety of deferasirox. Blood Rev 2:35–41CrossRefGoogle Scholar
  3. Clarke ET, Martell AE (1992) Stabilities of 1,2-dimethyl-3-hydroxypyrid-4-one chelates of divalent and trivalent metal ions. Inorg Chim Acta 19:57–63CrossRefGoogle Scholar
  4. Evans RW, Kong X, Hider RC (2012) Iron mobilization from transferrin by therapeutic iron chelating agents. Biochim Biophys Acta 1820:282–290PubMedCrossRefGoogle Scholar
  5. Fatemi SJ, Amiri A, Bazargan MH, Tubafard S, Fatemi SN (2007) Clinical evaluation of desferrioxamine (DFO) for removal of thallium ions in rat. Int J Artif Organs 30:902–905PubMedGoogle Scholar
  6. Fatemi SJ, Tubafard S, Nadi B (2009) Evaluation of the effect of cadmium on rat organs and investigation of diethyl carbamate as an oral drug in treatment of cadmium toxicity. Med Chem Res 18:179–186CrossRefGoogle Scholar
  7. Flora SJS, Bhattacharyan R, Vijayaraghavan R (1995) Combined therapeutic potential of meso dimercaptosuccinic acid and calcium edentate on the mobilization and distribution of lead in experimental lead intoxication in rats. Fundam Appl Toxicol 25:233–240PubMedCrossRefGoogle Scholar
  8. Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW (2010) Combined iron chelation therapy. Ann N Y Acad Sci 1202:79–86PubMedCrossRefGoogle Scholar
  9. Glickstein H, BenEl R, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI (2006) Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 108:3195–3203PubMedCrossRefGoogle Scholar
  10. Gomez W, Esparza JL, Domingo JL, Singha PK, Jones MM (1988) Comparative aluminium mobilizing action of desferrioxamine and four 3-hydroxypyrid-4-ones in aluminium-loaded rats. Toxicology 130:175–181CrossRefGoogle Scholar
  11. Grandjean P, White RF, Nielsen A, Cleary D, de Oliveira Santos EC (1999) Methylmercury neurotoxicity in Amazonian children downstream from gold mining. Environ Health Perspect 107:587–591PubMedCrossRefGoogle Scholar
  12. Gyparaki M, Porter JB, Hirani S, Streater M, Hider RC, Huehns ER (1987) In vivo evaluation of hydroxypyridone iron chelators in a mouse model. Acta Haematol 78:217–221PubMedCrossRefGoogle Scholar
  13. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G (2001) ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 97:1115–1122PubMedCrossRefGoogle Scholar
  14. Hider RC, Kontoghiorghes G and Silver J (1984) Pharmaceutical compositions. GB patent 2118176 AGoogle Scholar
  15. Kaur G, Srivastava UC, Dwivedi RS, Srivastava RC (1984) Influence of polyaminocarboxylic acids on the removal of manganese-54 from the body organs of sham-operated and partially hepatectomized rats. Toxicol Lett 22:1–6PubMedCrossRefGoogle Scholar
  16. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L (1987) Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J 295:1509–1512CrossRefGoogle Scholar
  17. Ma Y, Zhou T, Kong X, Hider RC (2012) Chelating agents for the treatment of systemic iron overload. Curr Med Chem 19:2816–2827PubMedCrossRefGoogle Scholar
  18. Magos L, Halbach S, Clarkson TW (1978) Role of catalase in the oxidation of mercury vapor. Biochem Pharmacol 27:1373–1377PubMedCrossRefGoogle Scholar
  19. Neufeld EJ (2006) Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 107(9):3436–3441PubMedCrossRefGoogle Scholar
  20. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a placebo-controlled, dose-escalation trial. Lancet 361:1597–1602PubMedCrossRefGoogle Scholar
  21. Steinhauser S, Heinz U, Bartholoma M, Weyhermu¨ller T, Nick H, Hegetschweiler K (2004) Complex formation of ICL670 and related ligands with Fe(III) and Fe(II). Eur J Inorg Chem 21:4177–4192CrossRefGoogle Scholar
  22. Tubafard S, Fatemi SJ (2008) Chelation of bismuth by combining desferrioxamine and deferiprone in rats. Toxicol Ind Health 24:235–240PubMedCrossRefGoogle Scholar
  23. Voskaridou E, Christoulas D, Terpos E (2011) Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol 154:654–656PubMedCrossRefGoogle Scholar
  24. Yang LPH, Keam SJ, Keating GM (2007) Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs 67:2211–2230PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Marzieh Iranmanesh
    • 1
  • S. Jamil A. Fatemi
    • 1
  • Mohammad Reza Golbafan
    • 1
  • Faezeh Dahooee Balooch
    • 1
  1. 1.Department of ChemistryShahid Bahonar University of KermanKermanIran

Personalised recommendations